{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.2","value":"279.8"},{"groupId":"OG001","spread":"27.7","value":"512.0"},{"groupId":"OG002","spread":"36.9","value":"258.8"},{"groupId":"OG003","spread":"40.91","value":"229.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"38"}],"units":"Participants"}],"description":"Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population (all dosed patients with at least one reportable AZD4205 plasma concentrations and no important AEs or protocol deviations that may impact PK) with Intensive PK sampling on Cycle 1, Day 1","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).","title":"Part A and Part B: Maximum Plasma Concentration (Cmax) of AZD4205","type":"SECONDARY","unitOfMeasure":"ng/mL"}